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Israel Gomy* and Maria Del Pilar Estevez DizAbstract
Hereditary cancer risk assessment (HCRA) is a multidisciplinary process of estimating probabilities of germline
mutations in cancer susceptibility genes and assessing empiric risks of cancer, based on personal and family history.
It includes genetic counseling, testing and management of at-risk individuals so that they can make well-informed
choices about cancer surveillance, surgical treatment and chemopreventive measures, including biomolecular
cancer therapies. Providing patients and family members with an appropriate HCRA will contribute to a better
process of making decisions about their personal and family risks of cancer. Following individuals at high risk
through screening protocols, reassuring those at low risk, and referring those at increased risk of hereditary cancer
to a cancer genetics center may be the best suitable approach of HCRA.
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Within the last decade, emerging biomolecular tech-
nologies, such as whole-exome and genome sequencing
and high-throughput genotyping have been rapidly
growing and enlightening the knowledge of inherited
cancer susceptibility. Meanwhile, important issues on
bench-to-bedside translation of these major breakthroughs
into clinical practice have been equally addressed. Never-
theless, one essential component of these aspects includes
the counseling of individuals with hereditary cancer risk.
The increased public awareness of the genetic aspects of
cancer susceptibility has resulted in more enquiries from
clinical and surgical oncologists about which would be the
best approach for their patients so that appropriate man-
agement could be provided.
More than fifty rare Mendelian cancer syndromes are
caused by highly penetrant germline mutations affecting
either tumor suppressor genes, DNA repair genes or
proto-oncogenes, mostly with autosomal dominant in-
heritance (Table 1). Their cumulative relative risks are
the highest ones (more than 10 times), dramatically af-
fecting the quality of life and decreasing its expectancy.
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distribution, and reproduction in any mediumalthough more prevalent in selected populations, and
increase approximately two to five times the general
population risk. Germline variants with low penetrance
are relatively common in most populations, and have
been identified through genome-wide association studies
(GWAS). Although their size effects are individually low
(< 1.5), they may be relevant on risk stratification. Actu-
ally, they explain part of the excess familial risk and the
so-called ‘missing heritability’ remains largely unknown
[1]. Nowadays, with the advance of next-generation se-
quencing and genotyping assays, more variants have been
identified, shedding new light on the genomic architecture
of the inherited susceptibility of cancer.
This review aims to describe a high-quality approach
of delivering hereditary cancer risk assessment (HCRA)
within a multidisciplinary context.Referrals for HCRA
In addition to age, a positive family history of cancer
is the single most important constitutional risk factor
for which early recognition and intervention could be
lifesaving.
Identifying the inherited risk factors of cancer in a
given individual or family is complex and raises import-
ant psychological, social, and ethical issues. It requires
the knowledge of genetics and oncology, besides suitable
communication skills, demanding more time than fromd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.




Hereditary breast and/or ovarian cancer BRCA1 Heterozygous High Breast cancer
BRCA2 Ovarian cancer
RAD51 (B,C,D) intermediate Pancreatic cancer
ATM intermediate Prostate cancer
CHEK2 intermediate Colorectal cancer





MMR cancer syndrome MMR genes Homozygous High Leukemia, lymphoma
Rhabdomyosarcoma




MYH-associated polyposis MUTYH Homozygous High Colorectal cancer
Polymerase proofreading-associated
polyposis
POLE Heterozygous High Colorectal cancer
POLD1 Endometrial cancer
Bloom syndrome BLM1 Homozygous High Leukemia
Colorectal cancer
Wilms tumor
Nijmegen syndrome NBS1 Homozygous High Lymphoma
Medulloblastoma
Rhabdomyosarcoma





Li-Fraumeni syndrome TP53 Heterozygous High Breast cancer
Li-Fraumeni like syndrome CHEK2 intermediate Sarcoma
Adrenocortical cancer
Brain tumor





Hereditary diffuse gastric cancer CDH1 Heterozygous High Diffuse gastric cancer
Lobular Breast cancer
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Table 1 Hereditary cancer syndromes (Continued)
Juvenile polyposis SMAD4 Heterozygous High Hamartomatous polyps
BMPR1A Colorectal cancer
Pancreatic cancer
Melanoma syndromes CDKN2A Heterozygous High Malignant melanoma
CDK4 Pancreatic cancer




Tuberous sclerosis TSC1 Heterozygous High Renal angiomyolipoma
TSC2 Subependimoma
Giant cell astrocytoma
Von Hippel-Lindau syndrome VHL Heterozygous High Hemangioblastomas
Renal cell cancer
Pheochromocytoma
Chuvash policitemia Homozygous High Vertebral angiomas
Birt-Hogg-Dubè syndrome FLCN Heterozygous High Renal cell cancer
Skin tumors
Papillary renal cancer syndromes FH Heterozygous High Renal cell cancer
MET
Retinoblastoma RB1 Heterozygous High Retinoblastoma
Hereditary Paraganglioma SDH (A, B, C, D) Heterozygous High Paraganglioma
Pheochromocytoma
Multiple Endocrine Neoplasia1 MEN1 Heterozygous High Pituitary adenoma
Multiple Endocrine Neoplasia2 RET Parathyroid adenoma
Medular thyroid cancer
Pheochromocytoma
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Oncology (ASCO), the National Society of Genetic
Counselors (NSGC), the Oncology Nursing Society
(ONS), and other health care professional organizations
have set forth guidelines outlining standards for the prac-
tice of cancer risk counseling, risk assessment, and genetic
testing [2-4]. It also includes genetic testing as appropriate
and management of at-risk individuals so that they can
make informed choices about cancer screening, surgical
and/or chemopreventive risk management options, as well
as targeted cancer therapies [5]. In Table 2 there are pos-
sible indications of referral for HCRA.Components of the HCRA
The genetic risk assessment of an individual with cancer
is based upon the careful analysis of the personal history,
detailed family history and physical examination when
appropriate. It requires confirmation of the diagnosis inaffected relatives, preferably through biopsies or, when-
ever possible, death certificates or autopsies.
These are some important issues to be addressed within
the HCRA process [5]:
1. Family pedigrees drawings with at least three
generations in both sides of family;
2. Patients and relatives:
a. Current age, age at diagnosis, age at death,
primary site, pathologic features, treatments;
b. Ancestry (especially if Ashkenazi Jewish);
c. Previous surgeries, biopsies, diseases;
d. Endogenous risk factors: age at menarche, fertility
history;
e. Exogenous risk factors: tobacco/alcohol use, food
intake, hormones, exercises;
f. Cancer screening: mammography, gastrointestinal
endoscopy, PSA;
g. Chemoprevention.
Table 2 Possible indications of referrals for hereditary cancer risk assessment
Personal history Family history
Early onset of cancer diagnosis (e.g. breast cancer < 45 years,
colorectal cancer < 50 years)
Three close relatives (same side) with cancer of the same or
syndromically related type (breast/ovary, colorectal/endometrium)
Multiple associated primary cancers: breast/ovary, colorectal/
endometrium
Two close relatives (same side) with cancer of the same or
related type with at least one affected under 50 years
Male breast cancer One first-degree relative with early onset cancer (breast < 45 years,
colorectal < 50 years)
Ovarian, fallopian tube, primary peritoneal cancer One first-degree relative with multiple primary cancers
Breast cancer and thyroid, sarcoma, adrenocortical carcinoma Two or more relatives with uncommon cancers (sarcoma, glioma,
hemangioblastoma, etc.)
Multiple colon polyps (>10 cumulative) Relatives of patients with known BRCA, APC, MUTYH, mismatch repair
mutations
Colorectal or endometrial cancer with microsattelite instability
and/or lack of expression of mismatch repair protein(s) by
immunohistochemistry
Many relatives with cancer but no criteria for testing are fulfilled
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circumference, tongue, oral mucosa, thyroid, hands
and feet, abdomen;
4. Psychosocial and family dynamic;
5. Basic principles of cancer genetics;
6. Differential diagnosis;
7. Mutation probabilities and empiric risks;
8. Pre-test genetic counseling:
a. Indentify the best individuals to test;
b. Prioritize order of testing (germline, tumor);
c. Explain test techniques, limitations, sensitivity/
specificity;
d. Facilitate informed consent: possible outcomes
(positive, true-negative, uninformative), costs,
turn-around-time, insurance coverage;
e. Address psychological, ethical, cultural,
communication issues.
9. Post-test genetic counseling:
a. Disclosure and interpretation of results;
b. Address psychological and ethical concerns;
c. Identify at-risk family members;
d. Discuss communication of results to at-risk
family members.
10.Personalized risk management strategies:
a. Screening/surveillance exams;
b. Risk reduction, cancer prevention (surgeries,
chemoprevention);
c. Empiric strategies for uninformative results.
Predicting germline mutations
Several models are available to estimate the likelihood of
detecting a mutation in a cancer-susceptibility gene and
each model is utilized selectively based on the character-
istics of the patient’s personal and family history.
If a mutation in the BRCA gene is suspected to be present
in a hereditary breast and ovarian cancer family, there are sev-
eral models available to predict the probability of an individualcarrying such a mutation. These models include the Couch
[6], Penn II [7], Myriad [8], BRCAPRO [9-11], Tyrer-Cuzick
[12], and BOADICEA models [13]. Such models incorporate
breast and ovarian cancer in first- and second-degree relatives,
age of onset of cancer, Ashkenazi Jewish ancestry, and some
are starting to incorporate other ethnic backgrounds.
There are similar models for predicting mutation in
DNA mismatch repair (MMR) genes in suspected Lynch
syndrome families, including Wijnen [14], MMRpro [15],
MMRpredict [16], and PREMM1,2,6 [17]. However, in the
HCRA of colon cancer families, it is more common to use
established criteria as an indication for testing, including
the Amsterdam I and II [18], or the revised Bethesda
Guidelines [19], which determine eligibility for tumor
analysis to detect microsatellite instability that would aid
to guide genetic testing of the MMR genes.
Furthermore, there are established diagnostic criteria
for Li-Fraumeni [20,21] and Cowden syndromes [22,23],
as well as mutation probability models for hereditary
melanoma [24] and pancreatic cancer (Table 3).
The use of mutation predictability models is import-
ant for several reasons. First, calculating the likelihood
of a germline mutation can help clinicians determine
which family member is the best candidate for testing.
Second, due to the high cost of genetic testing, numer-
ical calculations of mutation probability may provide
supportive evidence for insurance companies. Third, for
psychosocial reasons, patients who are informed with a
numerical estimation of a mutation may have more real-
istic expectations about the possibility of a positive re-
sult. Finally, for worried patients with a low probability
of carrying a mutation, and for those with mutations
without any influence in gene expression or stability,
numerical presentations may provide substantial re-
assurance regarding screening guidelines based on em-
piric cancer risks. A recent study highlighted possible
health benefits and the cost-effectiveness of primary
Table 3 Clinical criteria guidelines and mutation probability models utilized for HCRA
Syndrome Model Genes included* Clinical criteria/tumors included*
Hereditary breast and
ovarian cancer
Couch, Penn II, Myriad, Tyrer-Cuzick,
BRCAPRO, BOADICEA





Family history (one side)
Lynch Wijnen, MMRpro, MMRPredict,
PREMM1,2,6









Cowden Cleveland clinic PTEN International Cowden Consortium
Thyroid, oral papillomas, acral keratoses, skin lipomas,
trichilemmomas, uterine leiomyomas, gastrointestinal
polyps, dysplastic cerebellar gangliocytoma, fibrocystic
breast disease
Hereditary melanoma MELApro CDKN2A Melanoma
*included in mutation probability models.
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population [25].
Nevertheless, several models may underestimate mu-
tation probability in certain situations such as a limited
family structure or specific tumor characteristics [26].
Thus, probabilities predicted by a model must be inter-
preted in the context of an individual’s personal and
family history. The National Comprehensive Cancer
Network (NCCN) in USA publishes guidelines annually
in order to help clinicians to select which patients are
appropriate candidates for either genetic referral or
genetic testing [27,28].
Predicting cancer risks
In the absence of an identified gene mutation, counseling
unaffected individuals about their empiric risk of cancer
requires careful consideration of the patient’s personal and
family history.
Most risk estimates for cancer development are em-
pirical, based on the probability of a genetic component
in the individual, and this risk estimate increases if the
proband has several affected relatives on the same side
of family with the same or related cancers, multiple or
early onset cancers, or if the individual has clinical features
of a hereditary cancer syndrome [29].
For breast cancer, there are several models that esti-
mate empiric risks, including the Gail [30], Claus [31],
BRCAPRO [9-11], Tyrer-Cuzick [12] and BOADICEA[13] models. All of these models incorporate first-
degree relatives with breast cancer along with hormone
risk factors, although they may vary in which known
breast cancer risk factors are incorporated. There are
also some published tools available to assess risks for
colon, ovarian, lung and melanoma, but few are validated
[32]. However, for prostate cancer, whose familial risk is
known to be associated with dozens of low-penetrant vari-
ants [33], there is not a genetic model so far. Predictability
based on the number of affected relatives, degree of con-
sanguinity and also ancestry could be calculated by math-
ematical models to estimate empiric risks and possibly
guide recommendations for appropriate screening. The
undergoing discovery of functional alleles reinforces the
need for new models to incorporate them better address
cancer risk assessment.
Moreover, because those models that convert genotypes
into absolute risks are empirically derived, prospective re-
search is needed to confirm the accuracy of these predic-
tions and evaluate the effectiveness of interventions based
on individual genetic testing. For instance, the National
Institute for Health and Care Excellence (NICE) in the
United Kingdom recently released guidelines concerning
risk assessment and management of familial breast cancer,
even when testing is not performed [34].
How should risks be communicated? They can be given
as cancer risk per year, or before a certain age, or within a
decade, or as an overall lifetime risk in comparison with
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ual perception of cancer risk should be assessed, as should
its possible effects on the health and lifestyle behaviors.
Pre-test counseling
After establishing risks of identifying a pathogenic germ-
line mutation in a family and indicating the best candi-
dates to be tested, it follows the information process of
pre-test genetic counseling, which requires informed con-
sent for testing for a mutation in a cancer susceptibility
gene (see list below). It explains the eventual limitations of
testing, its possible results, the emotional impact that may
arise, and its relevance for employment and insurance.
This approach must be nondirective, letting patients make
their own decisions after knowing all possible scenarios
[35]. In some circumstances, a pathogenic mutation will
not be identified but genetic variants with unknown clin-
ical significance, requiring further testing and reclassifica-
tion. When a known deleterious mutation is detected in a
family member, and when the affected individual agrees to
release his/her results to the family, predictive testing can
be offered to at-risk relatives. Predictive testing often re-
quires two pre-test counseling interviews with up to three
months between them, when family, emotional, employ-
ment and insurance issues are discussed, as well inherit-
ance and penetrance of the mutation are explained.
Screening and preventive options should also be discussed
and it must be stressed that no surveillance guideline is
flawless, so individuals must bear in mind that abnor-
mal symptoms should never be ignored between screen-
ing exams [36].
Basic elements of informed consent for testing cancer
susceptibility genes
1. information on the specific mutation(s) being tested,
including whether the range of risk associated with
the variant will impact medical care;
2. implications of a positive and negative result;
3. possibility that the test will not be informative;
4. options for risk estimation without genetic testing;
5. risk of passing a genetic variant to children;
6. technical accuracy of the test including where
required by law, licensure of the laboratory;
7. fees involved in testing and counselling;
8. psychological implications of test results (benefits
and risks);
9. risks and protections against genetic discrimination
by employers or insurers;
10.confidentiality issues, including policies related to
privacy and data security;
11.possible use of DNA testing samples in future research;
12.options and limitations of medical surveillance and
strategies for prevention after genetic testing;13.importance of sharing genetic test results with at-
risk relatives so that they may benefit from this
information;
14.plans for follow-up after testing.
Post-test counseling
When an affected or unaffected patient chooses to
undergo testing, post-test counseling helps individuals
to interpret and understand their results, whether
positive, negative, undetermined or inconclusive. Psy-
chological support may be provided as ambiguity and
uncertainty may arise [35]. For example, individuals
with a low-risk result may suffer from “the survivor guilt”.
High-risk individuals may need to explain positive results
to their at-risk closest relatives and counselors (or ge-
neticists) can help sharing this information. It should be
emphasized that individuals who have had cancer may
be psychologically affected and feel guilty by knowing
their pathogenic germline mutation may be passed on
through their offspring. In addition, since early diagno-
sis of cancer improves outcome, a clear protocol for sur-
veillance and possible prophylactic measures must be
offered to those at greater risks, even if they refuse or
could not afford genetic testing. For example, risk-
reducing bilateral mastectomy when treating unilateral
breast cancer in a BRCA1/BRCA2 mutation carrier or
hysterectomy and bilateral salpingo-ooforectomy in a
MSH6 mutation carrier. However, the application of
such a system requires robust audit of outcomes, both
related to cancer morbidity and mortality, and of psy-
chological effects. Establishing a threshold level of risk
at which to offer screening is needed in order to assess
outcome. Those at moderately increased risk must en-
gage in surveillance strategies whose specificity, sensi-
tivity and cost-effectiveness should be addressed in the
long term [36].
Clinical sequencing
Very recently, the American College of Medical Genetics
and Genomics (ACMG) published a policy statement on
recommendations for reporting incidental findings–those
not related to the primary indication for testing but with
potential medical utility–in clinical exome and genome
sequencing. This working group presented a “minimum
list” of Mendelian disorders for which any known patho-
genic and expected pathogenic secondary variants would
be routinely reported to the clinician who ordered clinical
sequencing. The ACMG estimated that about 1% of se-
quencing results would include an incidental finding from
this list. Remarkably, 16 of 24 disorders (67%) are heredi-
tary cancer syndromes and 13/16 (81%) may be mani-
fested during childhood. As recommended, these variants
would be reported independently from patients’ prefer-
ences and age, and the ordering physician would be
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with pre-, post test counseling and follow up. The in-
formed consent guidelines for this clinical context are ex-
pected to be released soon [37].
Conclusions
In summary, HCRA is an information process of estimat-
ing probabilities of germline mutations in cancer suscepti-
bility genes and assessing empiric risks of cancer based on
personal and family history in order to offer molecular
diagnosis and clinical management. Providing patients
with pre-and post-test genetic counseling can help them
to achieve a better informed decision making. Following
individuals at high risk with surveillance protocols (such
as from NCCN and NICE), reassuring those at low risk,
and referring those at increased risk of a hereditary cancer
(whether carriers of primary or secondary variants) to a
cancer genetics center with multidisciplinary outpatient
clinics may allow the best suitable approach of HCRA.
Specialized nurses can be settled in district hospitals to
undertake pedigrees and risk assessment so they can refer
individuals at moderately increased risk for surveillance,
those at highly increased risk to the local cancer genetics
center and reassure those at low risk.
In Brazil, a National Familial Cancer Network has been
built in order to provide families with hereditary cancer a
prompt access to diagnosis, management and counseling
of the most common hereditary cancer syndromes in a
public health care setting [38].
Collaboration with associations of patients and non-
governmental foundations would be extremely helpful to
provide families with a better support and care.
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